Trial of canakinumab, an IL-1{beta} receptor antagonist, in patients with inclusion body myositis

Conclusions In this long-term, open-label study, canakinumab showed small, but not clinically appreciable, stabilizing benefits in 2 of 5 patients with sIBM over 1 year, was ineffective in 2 others, and might have worsened one. No patient improved. Classification of evidence This study provides Class IV evidence that canakinumab was ineffective for patients with sIBM.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: All Immunology, Muscle disease, Clinical trials Observational study (Cohort, Case control), Class IV Article Source Type: research